Fig. 1From: Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension studyPatient disposition. Evaluation of efficacy was based on patients remaining in the study (observed case analysis); accordingly, not all patients were assessed through to the last observation visit. AE adverse event, BID twice dailyBack to article page